Letter About “Seven Years of Febrile Neutropenia in Internal Medicine Department”
DOI:
https://doi.org/10.24950/rspmi/CE/148/19/3/2019Keywords:
Antineoplastic Agents/ adverse effects, beta- -Lactams, Chemotherapy-Induced Febrile Neutropenia, Febrile Neutropenia/ chemically inducedDownloads
References
Pinho M, Rodrigues C, Guedes L, Costa E, Gonçalves E, Sete Anos de Neutropenias Febris num Serviço de Medicina Interna. Rev Soc Port Med Interna. 2019; 26: 97-105.
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27:v111-v118.
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018, 36: 1443-53. doi: 10.1200/JCO.2017.77.6211.
Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013, 21:1487-95. doi: 10.1007/s00520-013-1758-y.
Bergstrom C, Nagalla S, Gupta A. Management of patients with febrile neutropenia: a teachable moment. JAMA Intern Med. 2018;178:558-9. doi: 10.1001/jamainternmed.2017.8386
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
